TARDBP and amyotrophic lateral sclerosis: Loss of TMEM106B activity and expression enhances TARDBP/TDP-43 burden and is proposed to be a key determinant in the development of TARDBP/TDP-43 proteinopathies, as seen in ALS and FTD [410].